Tarjoustasot
Määrä
Osto
355
Myynti
Määrä
2 024
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
Sijoittajakalenteri ei ole saatavilla | ||
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
23.9.23.9.For Ketamir-2, the single ascending dose study in phase 1 was a success in every meaning. According to given information, first phase 2 study with real patients will begin already during this year. The price of the stock is volatile but ready to raise at once, if the next phase will be as succesful as the results of earlier studies.- 7.3.7.3.According to March 4, 2025 information, the first two-part human study with Ketamir-2 is ready to start: https://finance.yahoo.com/news/mira-pharmaceuticals-announces-approval-initiation-130000869.html . According to ACCESS Newswire, ”This Phase 1, randomized, double-blind, placebo-controlled, single-center study is designed to evaluate the safety, tolerability, and pharmacokinetics of orally administered Ketamir-2 in healthy adult volunteers… …The Company expects Phase 1 to conclude by Q4 2025, paving the way for a Phase 2a study in neuropathic pain patients to be initiated by the end of the year.” The stock price has been low, again. So, I have taken it into account by increasing my share. I presume that the road during this year is going to be rocky, but the first human results are not so far away.
- 7.1.7.1.The stock price of MIRA Pharmaceuticals (MIRA) is up well more than 10 per cents today when writing this text. MIRA is a drug company without any drugs to sell. So, it is in the preclinical phase. Why is the price moving heavily down and upwards? MIRA has studied a drug (ketamine), which is nowadays given intravenously for patients with difficult neuropathic pain. However, MIRAs Ketamir-2 is a new ketamine analog, which can be administered orally. No needles or whatsoever! The basic studies and studies with mice have been succesful. Just in December 2024 MIRA has submitted an Investigational New Drug application to the U.S. Food and Drug Administration (FDA) for Ketamir-2 for the treatment of neuropathic pain. The 1st phase human studies are planned to begin during Q1/2025. The US-Europe (Netherland) cooperation to complete these studies is on its way. It is possible, that MIRA might need more money before it gets the first drug to the market. However, if the first human studies will be succesful, cooperation with big drug company/-ies becomes very possible. The market of neuropathic pain is very large and it is increasing continuously. To summarise, MIRA is a risky investment but it has a big, big potential to become a winner. The start of the very first human study is near. It is interesting to follow the company and to be with it as a private investor, who follows carefully how the stock price fluctuates in the near future.
·7.1.I bought these not too long ago but changed my mind because it is very volatile. But worth following the company as you say :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 23.9.23.9.For Ketamir-2, the single ascending dose study in phase 1 was a success in every meaning. According to given information, first phase 2 study with real patients will begin already during this year. The price of the stock is volatile but ready to raise at once, if the next phase will be as succesful as the results of earlier studies.
- 7.3.7.3.According to March 4, 2025 information, the first two-part human study with Ketamir-2 is ready to start: https://finance.yahoo.com/news/mira-pharmaceuticals-announces-approval-initiation-130000869.html . According to ACCESS Newswire, ”This Phase 1, randomized, double-blind, placebo-controlled, single-center study is designed to evaluate the safety, tolerability, and pharmacokinetics of orally administered Ketamir-2 in healthy adult volunteers… …The Company expects Phase 1 to conclude by Q4 2025, paving the way for a Phase 2a study in neuropathic pain patients to be initiated by the end of the year.” The stock price has been low, again. So, I have taken it into account by increasing my share. I presume that the road during this year is going to be rocky, but the first human results are not so far away.
- 7.1.7.1.The stock price of MIRA Pharmaceuticals (MIRA) is up well more than 10 per cents today when writing this text. MIRA is a drug company without any drugs to sell. So, it is in the preclinical phase. Why is the price moving heavily down and upwards? MIRA has studied a drug (ketamine), which is nowadays given intravenously for patients with difficult neuropathic pain. However, MIRAs Ketamir-2 is a new ketamine analog, which can be administered orally. No needles or whatsoever! The basic studies and studies with mice have been succesful. Just in December 2024 MIRA has submitted an Investigational New Drug application to the U.S. Food and Drug Administration (FDA) for Ketamir-2 for the treatment of neuropathic pain. The 1st phase human studies are planned to begin during Q1/2025. The US-Europe (Netherland) cooperation to complete these studies is on its way. It is possible, that MIRA might need more money before it gets the first drug to the market. However, if the first human studies will be succesful, cooperation with big drug company/-ies becomes very possible. The market of neuropathic pain is very large and it is increasing continuously. To summarise, MIRA is a risky investment but it has a big, big potential to become a winner. The start of the very first human study is near. It is interesting to follow the company and to be with it as a private investor, who follows carefully how the stock price fluctuates in the near future.·7.1.I bought these not too long ago but changed my mind because it is very volatile. But worth following the company as you say :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
355
Myynti
Määrä
2 024
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
Sijoittajakalenteri ei ole saatavilla | ||
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
Sijoittajakalenteri ei ole saatavilla | ||
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 23.9.23.9.For Ketamir-2, the single ascending dose study in phase 1 was a success in every meaning. According to given information, first phase 2 study with real patients will begin already during this year. The price of the stock is volatile but ready to raise at once, if the next phase will be as succesful as the results of earlier studies.
- 7.3.7.3.According to March 4, 2025 information, the first two-part human study with Ketamir-2 is ready to start: https://finance.yahoo.com/news/mira-pharmaceuticals-announces-approval-initiation-130000869.html . According to ACCESS Newswire, ”This Phase 1, randomized, double-blind, placebo-controlled, single-center study is designed to evaluate the safety, tolerability, and pharmacokinetics of orally administered Ketamir-2 in healthy adult volunteers… …The Company expects Phase 1 to conclude by Q4 2025, paving the way for a Phase 2a study in neuropathic pain patients to be initiated by the end of the year.” The stock price has been low, again. So, I have taken it into account by increasing my share. I presume that the road during this year is going to be rocky, but the first human results are not so far away.
- 7.1.7.1.The stock price of MIRA Pharmaceuticals (MIRA) is up well more than 10 per cents today when writing this text. MIRA is a drug company without any drugs to sell. So, it is in the preclinical phase. Why is the price moving heavily down and upwards? MIRA has studied a drug (ketamine), which is nowadays given intravenously for patients with difficult neuropathic pain. However, MIRAs Ketamir-2 is a new ketamine analog, which can be administered orally. No needles or whatsoever! The basic studies and studies with mice have been succesful. Just in December 2024 MIRA has submitted an Investigational New Drug application to the U.S. Food and Drug Administration (FDA) for Ketamir-2 for the treatment of neuropathic pain. The 1st phase human studies are planned to begin during Q1/2025. The US-Europe (Netherland) cooperation to complete these studies is on its way. It is possible, that MIRA might need more money before it gets the first drug to the market. However, if the first human studies will be succesful, cooperation with big drug company/-ies becomes very possible. The market of neuropathic pain is very large and it is increasing continuously. To summarise, MIRA is a risky investment but it has a big, big potential to become a winner. The start of the very first human study is near. It is interesting to follow the company and to be with it as a private investor, who follows carefully how the stock price fluctuates in the near future.·7.1.I bought these not too long ago but changed my mind because it is very volatile. But worth following the company as you say :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
355
Myynti
Määrä
2 024
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt